Weight Management

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Q&As
Interactive
Polls

FDA Alerts

FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
phone that says FDA
FDA Approval
FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin for Adults With Type 2 Diabetes
03/27/2026
Anthony Calabro, MA
The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.
03/27/2026
FDA Alert
patient holding pills
FDA Alert
FDA Approves Oral Semaglutide Pill for Chronic Weight Management
12/23/2025
Anthony Calabro, MA
The FDA has cleared a once-daily oral semaglutide treatment for adults with obesity or overweight and weight-related conditions, based on phase 3 OASIS 4 trial results demonstrating significant mean weight...
12/23/2025
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
Timeline Snapshot
physicians discussing cases
Timeline Snapshot
Notable FDA Alerts in April
04/30/2016
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
04/30/2016
Addiction
Addiction
FDA approves ADHD drug Vyvanse for binge-eating disorder
02/02/2015
The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.
02/02/2015